AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria

Daelyn Y. Richards, Shelley R. Winn, Sandra Dudley, Sean Nygaard, Taylor L. Mighell, Markus Grompe, Cary O. Harding

Research output: Contribution to journalArticle

Abstract

Phenylketonuria (PKU) due to recessively inherited phenylalanine hydroxylase (PAH) deficiency results in hyperphenylalaninemia, which is toxic to the central nervous system. Restriction of dietary phenylalanine intake remains the standard of PKU care and prevents the major neurologic manifestations of the disease, yet shortcomings of dietary therapy remain, including poor adherence to a difficult and unpalatable diet, an increased incidence of neuropsychiatric illness, and imperfect neurocognitive outcomes. Gene therapy for PKU is a promising novel approach to promote lifelong neurological protection while allowing unrestricted dietary phenylalanine intake. In this study, liver-tropic recombinant AAV2/8 vectors were used to deliver CRISPR/Cas9 machinery and facilitate correction of the Pahenu2 allele by homologous recombination. Additionally, a non-homologous end joining (NHEJ) inhibitor, vanillin, was co-administered with the viral drug to promote homology-directed repair (HDR) with the AAV-provided repair template. This combinatorial drug administration allowed for lifelong, permanent correction of the Pahenu2 allele in a portion of treated hepatocytes of mice with PKU, yielding partial restoration of liver PAH activity, substantial reduction of blood phenylalanine, and prevention of maternal PKU effects during breeding. This work reveals that CRISPR/Cas9 gene editing is a promising tool for permanent PKU gene editing.

Original languageEnglish (US)
Pages (from-to)234-245
Number of pages12
JournalMolecular Therapy - Methods and Clinical Development
Volume17
DOIs
StatePublished - Jun 12 2020

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Phenylketonurias
Phenylalanine
Maternal Phenylketonuria
Alleles
Phenylalanine Hydroxylase
Poisons
Liver
Homologous Recombination
Standard of Care
Neurologic Manifestations
Gene Editing
Nervous System Diseases
Pharmaceutical Preparations
Genetic Therapy
Breeding
Hepatocytes
Central Nervous System
Diet
Incidence

Keywords

  • CRISPR/Cas9
  • gene correction
  • gene editing
  • gene therapy
  • homology directed repair
  • phenylalanine
  • phenylalanine hydroxylase
  • phenylketonuria

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria. / Richards, Daelyn Y.; Winn, Shelley R.; Dudley, Sandra; Nygaard, Sean; Mighell, Taylor L.; Grompe, Markus; Harding, Cary O.

In: Molecular Therapy - Methods and Clinical Development, Vol. 17, 12.06.2020, p. 234-245.

Research output: Contribution to journalArticle

Richards, Daelyn Y. ; Winn, Shelley R. ; Dudley, Sandra ; Nygaard, Sean ; Mighell, Taylor L. ; Grompe, Markus ; Harding, Cary O. / AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria. In: Molecular Therapy - Methods and Clinical Development. 2020 ; Vol. 17. pp. 234-245.
@article{86fbf16a08fa406083988367975eac6f,
title = "AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria",
abstract = "Phenylketonuria (PKU) due to recessively inherited phenylalanine hydroxylase (PAH) deficiency results in hyperphenylalaninemia, which is toxic to the central nervous system. Restriction of dietary phenylalanine intake remains the standard of PKU care and prevents the major neurologic manifestations of the disease, yet shortcomings of dietary therapy remain, including poor adherence to a difficult and unpalatable diet, an increased incidence of neuropsychiatric illness, and imperfect neurocognitive outcomes. Gene therapy for PKU is a promising novel approach to promote lifelong neurological protection while allowing unrestricted dietary phenylalanine intake. In this study, liver-tropic recombinant AAV2/8 vectors were used to deliver CRISPR/Cas9 machinery and facilitate correction of the Pahenu2 allele by homologous recombination. Additionally, a non-homologous end joining (NHEJ) inhibitor, vanillin, was co-administered with the viral drug to promote homology-directed repair (HDR) with the AAV-provided repair template. This combinatorial drug administration allowed for lifelong, permanent correction of the Pahenu2 allele in a portion of treated hepatocytes of mice with PKU, yielding partial restoration of liver PAH activity, substantial reduction of blood phenylalanine, and prevention of maternal PKU effects during breeding. This work reveals that CRISPR/Cas9 gene editing is a promising tool for permanent PKU gene editing.",
keywords = "CRISPR/Cas9, gene correction, gene editing, gene therapy, homology directed repair, phenylalanine, phenylalanine hydroxylase, phenylketonuria",
author = "Richards, {Daelyn Y.} and Winn, {Shelley R.} and Sandra Dudley and Sean Nygaard and Mighell, {Taylor L.} and Markus Grompe and Harding, {Cary O.}",
year = "2020",
month = "6",
day = "12",
doi = "10.1016/j.omtm.2019.12.004",
language = "English (US)",
volume = "17",
pages = "234--245",
journal = "Molecular Therapy - Methods and Clinical Development",
issn = "2329-0501",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria

AU - Richards, Daelyn Y.

AU - Winn, Shelley R.

AU - Dudley, Sandra

AU - Nygaard, Sean

AU - Mighell, Taylor L.

AU - Grompe, Markus

AU - Harding, Cary O.

PY - 2020/6/12

Y1 - 2020/6/12

N2 - Phenylketonuria (PKU) due to recessively inherited phenylalanine hydroxylase (PAH) deficiency results in hyperphenylalaninemia, which is toxic to the central nervous system. Restriction of dietary phenylalanine intake remains the standard of PKU care and prevents the major neurologic manifestations of the disease, yet shortcomings of dietary therapy remain, including poor adherence to a difficult and unpalatable diet, an increased incidence of neuropsychiatric illness, and imperfect neurocognitive outcomes. Gene therapy for PKU is a promising novel approach to promote lifelong neurological protection while allowing unrestricted dietary phenylalanine intake. In this study, liver-tropic recombinant AAV2/8 vectors were used to deliver CRISPR/Cas9 machinery and facilitate correction of the Pahenu2 allele by homologous recombination. Additionally, a non-homologous end joining (NHEJ) inhibitor, vanillin, was co-administered with the viral drug to promote homology-directed repair (HDR) with the AAV-provided repair template. This combinatorial drug administration allowed for lifelong, permanent correction of the Pahenu2 allele in a portion of treated hepatocytes of mice with PKU, yielding partial restoration of liver PAH activity, substantial reduction of blood phenylalanine, and prevention of maternal PKU effects during breeding. This work reveals that CRISPR/Cas9 gene editing is a promising tool for permanent PKU gene editing.

AB - Phenylketonuria (PKU) due to recessively inherited phenylalanine hydroxylase (PAH) deficiency results in hyperphenylalaninemia, which is toxic to the central nervous system. Restriction of dietary phenylalanine intake remains the standard of PKU care and prevents the major neurologic manifestations of the disease, yet shortcomings of dietary therapy remain, including poor adherence to a difficult and unpalatable diet, an increased incidence of neuropsychiatric illness, and imperfect neurocognitive outcomes. Gene therapy for PKU is a promising novel approach to promote lifelong neurological protection while allowing unrestricted dietary phenylalanine intake. In this study, liver-tropic recombinant AAV2/8 vectors were used to deliver CRISPR/Cas9 machinery and facilitate correction of the Pahenu2 allele by homologous recombination. Additionally, a non-homologous end joining (NHEJ) inhibitor, vanillin, was co-administered with the viral drug to promote homology-directed repair (HDR) with the AAV-provided repair template. This combinatorial drug administration allowed for lifelong, permanent correction of the Pahenu2 allele in a portion of treated hepatocytes of mice with PKU, yielding partial restoration of liver PAH activity, substantial reduction of blood phenylalanine, and prevention of maternal PKU effects during breeding. This work reveals that CRISPR/Cas9 gene editing is a promising tool for permanent PKU gene editing.

KW - CRISPR/Cas9

KW - gene correction

KW - gene editing

KW - gene therapy

KW - homology directed repair

KW - phenylalanine

KW - phenylalanine hydroxylase

KW - phenylketonuria

UR - http://www.scopus.com/inward/record.url?scp=85077740863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077740863&partnerID=8YFLogxK

U2 - 10.1016/j.omtm.2019.12.004

DO - 10.1016/j.omtm.2019.12.004

M3 - Article

AN - SCOPUS:85077740863

VL - 17

SP - 234

EP - 245

JO - Molecular Therapy - Methods and Clinical Development

JF - Molecular Therapy - Methods and Clinical Development

SN - 2329-0501

ER -